Effects of Extracorporeal Blood Flow Rates on Patient Tolerance for LIXELLE® Treatment during Outpatient Hemodialysis
Blood Purification · 2024
DOI: 10.1159/000536075 ↗Kurz gefasst
Fachartikel in der Zeitschrift Blood Purification, 2024. Verfasst von Onkar S Dhande und 8 weiteren Autor:innen. Beteiligte Einrichtung: Alkahest, Inc., A Grifols Company, San Carlos, California, USA. Hauptthemen laut MEDLINE: Renal Dialysis, Kidney Failure, Chronic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 13 Literaturangaben.
Abstract (Originalsprache)
Introduction
Accumulation of β2-microglobulin (B2M) in dialysis patients contributes to several comorbidities of end-stage kidney disease (ESKD). The LIXELLE® device adsorbs B2M from blood using sorbent bead technology. Studies in Japan showed that LIXELLE treatment during hemodialysis (HD) at blood flow rates up to 250 mL/min removes B2M above HD alone and is well tolerated. We investigated tolerance for LIXELLE treatment during HD at higher HD blood flow rates standard in the USA.
Methods
A prospective, open-label, non-randomized, single-arm, early-feasibility study (EFS) assessed tolerance and safety of LIXELLE treatment during HD at blood flow rates up to 450 mL/min. ESKD patients (40–75 years old) on thrice weekly outpatient HD were eligible. After a 1-week HD run-in, patients received LIXELLE plus HD at a blood flow rate of 250 mL/min (1 week), followed by LIXELLE plus HD at a blood flow rate up to 450 mL/min (1 week). These blood flow rates were tested with three LIXELLE column sizes in sequence (treatment = 6 weeks). B2M removal was assessed for each combination.
Results
Ten patients with a historic intradialytic hypotension (IDH) rate of 0.42 events/HD session/patient were enrolled. Nine patients completed all combinations without IDH events (treatment IDH rate: 0.56 events/HD session/patient). No treatment-emergent serious adverse events or significant changes in red blood cell, platelet, or complement indices except haptoglobin were reported. B2M reduction ratios and removal of select proteins (<40 kDa) increased with escalating column size and blood flow rate.
Conclusion
LIXELLE plus HD across all column sizes was safe and well tolerated at blood flow rates up to 450 mL/min. Extent of B2M removal corresponded to column size-blood flow rate combinations. This EFS provides a risk profile to guide further studies of LIXELLE in ESKD patients at US-standard blood flow rates.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Alkahest, Inc., A Grifols Company, San Carlos, California, USA.
- South Texas Renal Care Group, San Antonio, Texas, USA.
- Kaneka Medix Corporation, Osaka, Japan.
- Division of Nephrology, Department of Medicine, University of New Mexico, Albuquerque, New Mexico, USA.
Zitieren
APA
Dhande, O. S., Teichert, A., Broumand, V., Kakita, H., Kitamura, A., Fukunishi, M., Argyropoulos, C. P., Czirr, E., & Nelson, P. J. (2024). Effects of Extracorporeal Blood Flow Rates on Patient Tolerance for LIXELLE® Treatment during Outpatient Hemodialysis. Blood Purification. https://doi.org/10.1159/000536075
Vancouver
Dhande OS, Teichert A, Broumand V, Kakita H, Kitamura A, Fukunishi M, et al. Effects of Extracorporeal Blood Flow Rates on Patient Tolerance for LIXELLE® Treatment during Outpatient Hemodialysis. Blood Purification. 2024. doi:10.1159/000536075
BibTeX
@article{Dhande2024,
author = {Dhande, Onkar S and Teichert, Arnaud and Broumand, Varshasb and Kakita, Haruki and Kitamura, Ayaka and Fukunishi, Masaaki and Argyropoulos, Christos P and Czirr, Eva and Nelson, Peter J},
title = {Effects of Extracorporeal Blood Flow Rates on Patient Tolerance for LIXELLE® Treatment during Outpatient Hemodialysis},
journal = {Blood Purification},
year = {2024},
doi = {10.1159/000536075}
}
EUVIMED